1. Home
  2. NUVL vs FAF Comparison

NUVL vs FAF Comparison

Compare NUVL & FAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$104.39

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo First American Corporation (New)

FAF

First American Corporation (New)

HOLD

Current Price

$64.69

Market Cap

6.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
FAF
Founded
2017
1889
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
6.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
FAF
Price
$104.39
$64.69
Analyst Decision
Strong Buy
Buy
Analyst Count
14
4
Target Price
$134.29
$76.00
AVG Volume (30 Days)
828.0K
477.3K
Earning Date
10-30-2025
10-22-2025
Dividend Yield
N/A
3.44%
EPS Growth
N/A
428.61
EPS
N/A
4.65
Revenue
N/A
$7,087,600,000.00
Revenue This Year
N/A
$20.14
Revenue Next Year
N/A
$7.43
P/E Ratio
N/A
$13.76
Revenue Growth
N/A
20.70
52 Week Low
$55.54
$53.09
52 Week High
$112.88
$68.64

Technical Indicators

Market Signals
Indicator
NUVL
FAF
Relative Strength Index (RSI) 51.87 54.51
Support Level $103.52 $61.85
Resistance Level $107.99 $65.07
Average True Range (ATR) 3.18 1.20
MACD -0.93 -0.11
Stochastic Oscillator 10.43 59.83

Price Performance

Historical Comparison
NUVL
FAF

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About FAF First American Corporation (New)

First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.

Share on Social Networks: